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Abstract
Roche's protease inhibitor nelfinavir mesylate (Viracept®) produced between March 2007-June
2007 was found to contain elevated levels of ethyl methanesulfonate (EMS), a known mutagen
(alkylator) – leading to a global recall of the drug. EMS levels in a daily dose (2,500 mg Viracept/day)
were predicted not to exceed a dose of ~2.75 mg/day (~0.055 mg/kg/day based on 50 kg patient).
As existing toxicology data on EMS did not permit an adequate patient risk assessment, a
comprehensive animal toxicology evaluation of EMS was conducted. General toxicity of EMS was
investigated in rats over 28 days. Two studies for DNA damage were performed in mice;
chromosomal damage was assessed using a micronucleus assay and gene mutations were detected
using the MutaMouse transgenic model. In addition, experiments designed to extrapolate animal
exposure to humans were undertaken. A general toxicity study showed that the toxicity of EMS
occurred only at doses ≥ 60 mg/kg/day, which is far above that received by patients. Studies for
chromosomal damage and mutations in mice demonstrated a clear threshold effect with EMS at 25
mg/kg/day, under chronic dosing conditions. Exposure analysis (Cmax) demonstrated that ~370-fold
higher levels of EMS than that ingested by patients, are needed to saturate known, highly conserved,
error-free, mammalian DNA repair mechanisms for alkylation. In summary, animal studies
suggested that patients who took nelfinavir mesylate with elevated levels of EMS are at no increased
risk for carcinogenicity or teratogenicity over their background risk, since mutations are
prerequisites for such downstream events. These findings are potentially relevant to >40 marketed
drugs that are mesylate salts.
Findings
Nelfinavir mesylate (Viracept®) is a protease inhibitor for
the treatment of HIV-infected patients produced by Roche
outside the US, Canada and Japan (in these regions it is
manufactured by Pfizer and marketed by Pfizer or Japan
Tobacco). It was first introduced by Roche in 1998 follow-
ing FDA approval in 1997. Although newer protease
inhibitors have become available for the treatment of
HIV, nelfinavir is seen as a useful medicine for: HIV-
infected patients who are intolerant to ritonavir, since it
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does not require ritonavir PK enhancement (boosting),
HIV-infected pregnant women, and HIV patients in
resource-limited settings since the formulation is heat-sta-
ble and does not require refrigeration.
In mid-May 2007, Roche received reports from France and
Spain of a strange odour associated with bottles of nelfi-
navir, including one patient reporting nausea and vomit-
ing. Investigations revealed that there were elevated levels
of ethyl methanesulfonate (EMS) in nelfinavir batches
produced between March 2007 and May 2007. Further
investigation revealed this to be due to manufacturing
issues, more specifically failure to dry the hold tank fol-
lowing ethanol cleaning. As EMS is a known alkylating
agent that acts on DNA to produce mutagenic and carci-
nogenic effects in animals, this led to a global recall of the
drug on June 6, 2007 facilitated via an extensive commu-
nication programme managed by Roche. Subsequent ret-
rospective testing of all nelfinavir batches produced since
1998 showed negligible levels (<1 ppm) in most batches
but a few incidences in May 2004 and June 2005 of the
presence of approximately 100 ppm of EMS prior to
March 2007 [1].
Based on the highest amount of EMS found in nelfinavir
tables (920 ppm), the EMS levels in a daily dose of nelfi-
navir (2,500 mg nelfinavir/day [10 tablets]) were shown
to result in a daily dose of EMS no higher than ~2.75 mg/
day (~0.055 mg/kg/day based on the conservative
assumption of a 50 kg patient). As it was crucial to under-
stand the potential risks to patients exposed to this level
of EMS over this period, Roche (with agreement from the
health authorities) designed both a comprehensive pre-
clinical toxicology programme and safety follow-up regis-
tries of exposed patients.
Pre-clinical program
EMS is formed from methanesulfonic acid and ethanol; it
is not thought to occur in nature and has no commercial
uses. EMS is, however, a known trace impurity in pharma-
ceuticals formulated as mesylate salts and for this reason
it is considered an impurity rather than a contaminant.
EMS is capable of inducing gene mutations and chromo-
somal aberrations via alkylation, mainly at the O6 posi-
tion of the guanine base [2]. Alkylation at this site of the
DNA is repaired (error-free repair) by a specific cellular
suicide "enzyme" called O6-methyl guanine methyltrans-
ferase (MGMT) [2]. Human risk assessments for direct
alkylating agents such as EMS are normally based on a lin-
ear dose response, i.e. a 'safe dose level' (threshold) can
not be calculated. However, recently published in vitro
data by Doak et al., indicated a threshold response at low
doses of EMS [3].
The pre-clinical programme focused on three key areas:
the general toxicity of EMS, the genotoxicity of EMS and
the subsequent analysis to extrapolate the findings to
humans.
General toxicity study
A general toxicity study was undertaken in rats and was
designed to identify any potential organ toxicities and
clinical chemistry/haematology changes. EMS was admin-
istered daily by oral gavage to rats of both sexes at dose
levels of 20, 60 and 180 mg/kg/day for a period of 28 days
[4]. No adverse effects were observed in rats at a dose of
20 mg/kg/day (compared to the highest potential patient
exposure of EMS of 0.055 mg/kg/day). At doses of 60 mg/
kg/day or above, changes associated with toxicity such as
decreased cell counts, and decreased organ weight/size
were seen in bone marrow, blood cells, testes and lym-
phatic tissues (as would be expected for an alkylating
agent) [4]. Importantly, no necrotic or pre-cancerous
lesions, nor major changes in laboratory values, were
observed even at the highest dose, over the 28 days.
Genotoxicity studies
Two separate assays were used to assess the genotoxicity of
EMS. Firstly, a micronucleus test (MNT) in bone marrow
cells of mice was conducted to investigate the dose-
response of chromosome damage induction at low doses
of EMS [5]. Secondly, a large MutaMouse™ study was
undertaken to investigate the dose-response of gene muta-
tion induction in the transgenic lacZ reporter gene at low
doses of EMS [5].
The MNT assay was performed as previously described [5].
The results are shown in Figure 1. The positive control,
ethyl nitrosourea (ENU), a genotoxic agent that induces a
similar spectrum of DNA adducts but in distinctively dif-
ferent proportions than EMS [6], demonstrated a clear lin-
ear response with regards to micronucleus induction. In
contrast, EMS showed a threshold dose-response with no
EMS and ENU: induction of micronuclei in mouse bone mar- row after 7 days of treatment Figure 1
EMS and ENU: induction of micronuclei in mouse 
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micronuclei induction at EMS doses up to, and including,
80 mg/kg/day.
MutaMouse assay
The MutaMouse assay – an assay that uses transgenic mice
to evaluate the induction of specific gene mutations – was
performed as previously described [5]. Similar to that
observed with the MNT, the MutaMouse study demon-
strated a clear threshold effect for mutations with EMS at
25 mg/kg/day in both bone marrow (Figure 2) and gas-
trointestinal tract, and 50 mg/kg/day in liver tissue (data
not shown), under chronic dosing conditions. These
experiments also indicated that the genotoxic effect of
ENU is independent of dose fractionation – i.e., when the
dose is given at one time or over 30 days (Figure 3). In
contrast, for EMS the single dose treatment (350 mg/kg)
clearly induced mutations whereas the 4-week, chronic
dosing with 12.5 mg/kg/day for 30 days (total dose 350
mg) showed no mutation induction – suggesting that any
mutations that are induced are repaired via the MGMT
repair mechanism. The results of the genotoxicity studies
described here were probed with statistical methods,
which yielded clear evidence for a hockey-stick dose-
response relationship, i.e. a dose-response with a thresh-
old below which exposure occurs but no genotoxic (and
hence no teratogenic or carcinogenic) effect versus the
spontaneous background is seen. The assumption of line-
arity could be reliably refuted for all parts of the studies
[7].
The last phase of the pre-clinical program was to extrapo-
late these findings to humans (in the absence of obtaining
human measurements) to facilitate a retrospective expo-
sure determination in patients having taken nelfinavir
containing elevated levels of EMS. The first step was to
generate a reliable EMS PK model by administering EMS
both orally and intravenously to mice and rats. The results
showed that EMS exhibits a high oral bioavailability
(~100%), high clearance (~0.6 mL/min/kg) and limited
volume of distribution corresponding to total body water
(~0.5 L/kg). The model was then validated using actual
data (oral and intravenous administration) from mice
(data not shown).
The availability of this comprehensive PK model allowed
for the estimation of the EMS PK profile in humans in
which a conservative scenario was assumed with 100%
bioavailability and a very low clearance. Using this model
the following parameters were calculated: Cmax = 0.85 μM,
AUC = 13 μM*h and half-life = 11 hr, a half-life similar to
that of EMS in buffer alone [8,9].
Comparing the retrospectively calculated exposure (Cmax)
of humans (0.85 μM) to free EMS (in nelfinavir) with the
exposure of EMS at the threshold based on the animal
experiments (315 μM) showed that ~370-fold higher lev-
els of EMS, than that ingested by patients (based on the
conservative estimation of an EMS dose in nelfinavir of
0.055 mg/kg/day), are needed to saturate known, highly-
conserved, error-free, mammalian DNA repair mecha-
nisms for alkylation (Figure 4) [10].
For an error-free repair mechanism of DNA damage, Cmax
is most likely the relevant determinant for safety margin
assessment at doses below the threshold. However, the
safety margin was also calculated based on the more con-
servative exposure measure of AUC and this showed that
~30-fold higher levels of EMS, than that ingested by
Induction of lacZ mutations in bone marrow as a function of  dose Figure 2
Induction of lacZ mutations in bone marrow as a 
function of dose.
Induction of LacZ mutations in bone marrow after single  dose and 4-week chronic dosing with EMS and ENU (effects  plotted against the cumulative dose) Figure 3
Induction of LacZ mutations in bone marrow after 
single dose and 4-week chronic dosing with EMS and 
ENU (effects plotted against the cumulative dose).
EMS single dose day 7     
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patients were required to saturate the DNA repair mecha-
nisms (data not shown) [10].
Conclusion
Extensive animal studies, which were deemed relevant
and predictive for the human situation by the European
Medicines Agency (EMEA), indicate that EMS exhibits a
threshold response for chromosome damage and muta-
tions when administered at doses below 25 mg/kg/day.
This threshold dose is far above that estimated as a worse
case to have been received by nelfinavir patients (0.055
mg/kg/day). Following extrapolation of these animal data
to humans, it was demonstrated that even at an exposure
level of 30 to 370-fold higher than that ingested by nelfi-
navir patients, the damage incurred by EMS on DNA can
still effectively be dealt with by DNA repair mechanisms.
Since chromosome damage and mutations are the under-
lying molecular events for teratogenicity and carcino-
genicity of alkylating agents like EMS, experts and the
EMEA agreed that the studies above could be used to
assess these risks for potentially affected nelfinavir
patients, with adequate reassurance on margins of safety.
In light of these extensive data – both independent experts
in toxicology, epidemiology and HIV clinical manage-
ment, together with the EMEA's Committee for Medicinal
Products for Human Use (CHMP), recommended that ret-
rospective patient registries were not required as there was
no indication that patients had been exposed to levels of
EMS that would result in permanent DNA damage. In the
context of pharmacovigilance for marketed drugs, this was
the first case in which a post-marketing safety event was
completely and thoroughly addressed with animal toxico-
logical investigations obviating the need for patient regis-
tries [11].
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